Pharmacovigilance data flagged 1,200–1,233 suspected post-vaccination deaths in the first two months, while Germany’s PEI recorded 2,133 reports; causal review linked only ~150–300, yet a VAERS-style 10–30× underreporting multiplier projects 20,000–60,000 potential vaccine-related deaths.

COVID vaccine sales generated between about $70 billion and over $100 billion in revenue, and upcoming-quarter revenue is expected at $13.83 billion (up 0.9%) while EPS is projected to fall nearly 20%.

Comirnaty’s fast-track approval skipped standard carcinogenicity and reproductive-toxicity studies under time pressure, fueling expert extrapolations of 20 000–60 000 German deaths from 2 133 reported cases. German health authorities and the EMA counter that pharmacovigilance reviews of ~190 million doses causally link only ~150–300 fatalities, with final causal verdicts in the low hundreds. National cohort studies show vaccinated groups with lower all-cause mortality, and safety reports list over 1 200 adverse-event categories for monitoring rather than confirmed effects.

Observers expect serious safety gaps in mRNA vaccine approvals—citing skipped toxicology tests, political favoritism, and potential tens of thousands of vaccine-attributed deaths—while regulators and real-world studies insist vaccines saved lives with no data supporting widespread mortality.